Clinical Research Directory
Browse clinical research sites, groups, and studies.
Organ Culture for Endocrine Resistant Next Line: A Treatment Selection Study in Metastatic Breast Cancer
Sponsor: Tel-Aviv Sourasky Medical Center
Summary
This study evaluates whether testing fresh tumor samples outside the body can help guide treatment selection for patients with hormone receptor-positive, HER2-negative metastatic breast cancer that has progressed during endocrine therapy. A biopsy sample from each participant will be tested using an ex vivo organ culture (EVOC) platform, which preserves the tumor tissue and allows researchers to assess its response to different anticancer treatments. The results will be used to help select the participant's next systemic treatment. The main objective is to evaluate the proportion of patients whose cancer responds to treatment selected using this approach. The study will also assess how long the cancer remains controlled, overall survival, and the relationship between laboratory test results and clinical outcomes.
Official title: OCEAN: Organ Culture for Endocrine Resistant Next Line - Treatment Selection Based on Fresh Tumor Samples in Metastatic Breast Cancer
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
39
Start Date
2024-06-14
Completion Date
2029-12-31
Last Updated
2026-10-26
Healthy Volunteers
No
Interventions
cResponse Ex Vivo Organ Culture (EVOC) Drug Sensitivity Assay
Fresh tumor tissue obtained by biopsy will undergo functional drug sensitivity testing using the cResponse ex vivo organ culture (EVOC) platform. Tumor samples will be exposed to a panel of anticancer agents, and treatment-specific response scores will be generated. The assay results will guide selection of the next available systemic anticancer treatment.
Locations (1)
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel